IN8bio Inc (INAB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$1.08-5.26%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Lower negative cash from operations to <= -$4.9 million by 2026-Q1: metric not reported.
IN8bio is cutting losses from $8.6M to $5.1M by 2026-Q1. Cash burn also improved from $6.1M to $4.9M. The company is focused on cancer therapies with new cell treatments. Recent earnings beats show some progress.
The company still loses over $2 per share in 2026. It has no revenue now and no clear growth. Leadership changes and failed deals raise risks. The stock is down 25% from its high.
The market prices in ongoing losses and no revenue growth. Our view sees risk in the slow progress and high losses.
Breaks if: net income losses exceed -$5.1 million beyond 2026-Q1
Control operating expenses and cash burn while maintaining sufficient cash position to support operations.
Stated as a priority in 8 of last 8 quarters. The company reported net losses ranging from $3.9 million to $7.1 million over this period, with $4.8 million loss in 2026-Q2. Cash decreased from $21.9 million in 2026-Q1 to $18.0 million in 2026-Q2. Management continues to manage operating losses and cash flow, but the trajectory shows ongoing losses and cash burn consistent with clinical-stage biopharma operations.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is cautious, as the company is loss-making and faces high risks, but there is potential for upside if sector trends remain favorable.
The market appears to be pricing in a challenging outlook given the company's recent weak financial performance and loss-making status. Expectations may be low, especially if guidance cuts occur, which could lead to further downward adjustments.
Management is focused on advancing key programs, particularly in glioblastoma treatment and T cell engagement, which could provide some positive momentum. However, the overall financial performance remains weak, and near-term risks are elevated due to the company's smaller size and industry volatility.
The thesis hinges on several factors, including management's ability to deliver on clinical milestones and the performance of sector bellwethers. Additionally, broader economic indicators, such as job reports, could impact investor sentiment and stock performance.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats impacting the thesis at this time.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Net loss of $4.8 million, cash of $18.0 million as of June 30, 2026.”
“Net loss of $5.1 million, cash of $21.9 million as of March 31, 2026.”
“Net loss of $4.9 million, cash of $27.1 million as of December 31, 2025.”
“Net loss of $3.9 million, cash of $27.1 million as of September 30, 2025.”
“Net loss of $5.1 million, cash of $27.1 million as of June 30, 2025.”
“Net loss of $5.6 million, cash of $27.1 million as of March 31, 2025.”
“Net loss of $6.2 million, cash of $27.1 million as of December 31, 2024.”
“Net loss of $7.1 million, cash of $27.1 million as of September 30, 2024.”
Breaks if: clinical trial progress stalls or fails
Breaks if: cash burn exceeds -$4.9 million beyond 2026-Q1
Control operating expenses and cash burn while maintaining sufficient cash position to support operations.
Stated as a priority in 8 of last 8 quarters. The company reported net losses ranging from $3.9 million to $7.1 million over this period, with $4.8 million loss in 2026-Q2. Cash decreased from $21.9 million in 2026-Q1 to $18.0 million in 2026-Q2. Management continues to manage operating losses and cash flow, but the trajectory shows ongoing losses and cash burn consistent with clinical-stage biopharma operations.
“Net loss of $4.8 million, cash of $18.0 million as of June 30, 2026.”
“Net loss of $5.1 million, cash of $21.9 million as of March 31, 2026.”
“Net loss of $4.9 million, cash of $27.1 million as of December 31, 2025.”
“Net loss of $3.9 million, cash of $27.1 million as of September 30, 2025.”
“Net loss of $5.1 million, cash of $27.1 million as of June 30, 2025.”
“Net loss of $5.6 million, cash of $27.1 million as of March 31, 2025.”
“Net loss of $6.2 million, cash of $27.1 million as of December 31, 2024.”
“Net loss of $7.1 million, cash of $27.1 million as of September 30, 2024.”
Over the next 1 to 3 years, INAB's prospects will depend heavily on execution and external market conditions. Not investment advice.